[go: up one dir, main page]

SI3586826T1 - Sestavki in postopki za stabilizacijo formulacij, ki vsebujejo beljakovine - Google Patents

Sestavki in postopki za stabilizacijo formulacij, ki vsebujejo beljakovine

Info

Publication number
SI3586826T1
SI3586826T1 SI201131987T SI201131987T SI3586826T1 SI 3586826 T1 SI3586826 T1 SI 3586826T1 SI 201131987 T SI201131987 T SI 201131987T SI 201131987 T SI201131987 T SI 201131987T SI 3586826 T1 SI3586826 T1 SI 3586826T1
Authority
SI
Slovenia
Prior art keywords
compositions
methods
containing formulations
stabilizing protein
stabilizing
Prior art date
Application number
SI201131987T
Other languages
English (en)
Inventor
Osigwe Esue
Vikas K. Sharma
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI3586826T1 publication Critical patent/SI3586826T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Saccharide Compounds (AREA)
SI201131987T 2010-06-24 2011-06-23 Sestavki in postopki za stabilizacijo formulacij, ki vsebujejo beljakovine SI3586826T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35810510P 2010-06-24 2010-06-24
EP19167191.6A EP3586826B1 (en) 2010-06-24 2011-06-23 Compositions and methods for stabilizing protein-containing formulations

Publications (1)

Publication Number Publication Date
SI3586826T1 true SI3586826T1 (sl) 2021-09-30

Family

ID=44628056

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201131803T SI2585045T1 (sl) 2010-06-24 2011-06-23 Sestavki in postopki, ki vsebujejo alkilglikozide za stabilizacijo formulacij, ki vsebujejo beljakovine
SI201131987T SI3586826T1 (sl) 2010-06-24 2011-06-23 Sestavki in postopki za stabilizacijo formulacij, ki vsebujejo beljakovine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201131803T SI2585045T1 (sl) 2010-06-24 2011-06-23 Sestavki in postopki, ki vsebujejo alkilglikozide za stabilizacijo formulacij, ki vsebujejo beljakovine

Country Status (19)

Country Link
US (4) US9254321B2 (sl)
EP (3) EP4008313A1 (sl)
JP (1) JP5894154B2 (sl)
KR (2) KR102058307B1 (sl)
CN (1) CN103068367B (sl)
AU (1) AU2011270828B2 (sl)
BR (1) BR112012033002B1 (sl)
CA (2) CA2802756C (sl)
ES (2) ES2880802T3 (sl)
HR (2) HRP20191878T1 (sl)
IL (2) IL223651A (sl)
MX (1) MX339666B (sl)
MY (2) MY161390A (sl)
NZ (1) NZ605147A (sl)
PL (2) PL3586826T3 (sl)
SG (1) SG186783A1 (sl)
SI (2) SI2585045T1 (sl)
WO (1) WO2011163458A2 (sl)
ZA (1) ZA201209539B (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3586826T3 (pl) * 2010-06-24 2021-10-25 F. Hoffmann-La Roche Ag Kompozycje i sposoby stabilizowania preparatów zawierających białka
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
MY174679A (en) * 2013-03-13 2020-05-06 Genentech Inc Formulations with reduced oxidation
WO2015032972A1 (en) * 2013-09-09 2015-03-12 Lek Pharmaceuticals D.D. Nanoformulation of g-csf for non-parenteral delivery
WO2015032981A1 (en) * 2013-09-09 2015-03-12 Lek Pharmaceuticals D.D. Erythropoietin conjugates having oral bioavailability
EP3052604B1 (en) * 2013-09-30 2023-05-31 Enza Biotech AB Use of alkylglycosides surfactants
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2018013673A1 (en) 2016-07-13 2018-01-18 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
WO2019036619A1 (en) * 2017-08-18 2019-02-21 Reform Biologics, Llc STABILIZING EXCIPIENTS FOR FORMULATIONS OF THERAPEUTIC PROTEIN
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
WO2021107033A1 (ja) * 2019-11-29 2021-06-03 千寿製薬株式会社 医薬組成物
CN117599193A (zh) * 2023-11-24 2024-02-27 皓阳生物科技(上海)有限公司 包含抗原和表面活性剂的物质组合物及其制备方法与应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DK166762B1 (da) * 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
EP0420937B1 (en) 1988-06-21 1994-11-09 Genentech, Inc. Therapeutic compositions for the treatment of myocardial infarction
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
EP1260521B1 (en) 1991-08-14 2007-11-21 Genentech Inc. Immunoglobulin variants for specific Fc epsilon receptors
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
ATE161192T1 (de) 1992-08-21 1998-01-15 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP1013270A3 (en) 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
ES2108566T3 (es) 1993-12-10 1997-12-16 Genentech Inc Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos.
ATE164079T1 (de) 1994-01-18 1998-04-15 Genentech Inc Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
DE69519382T3 (de) 1994-09-09 2008-09-18 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
RU2161502C2 (ru) 1995-06-07 2001-01-10 Элкермес Контролд Терапьютикс, Инк. Композиция для пролонгированного высвобождения гормона роста человека
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
DK1516628T3 (da) * 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
EP1297847A3 (en) 1996-01-23 2003-05-07 Genentech, Inc. Anti-CD18 antibodies in stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
ATE267257T1 (de) 1996-11-27 2004-06-15 Genentech Inc Humanisierte anti-koerper gegen cd11a
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PL203326B1 (pl) 1999-06-25 2009-09-30 Genentech Inc Przeciwciało, kompozycja farmaceutyczna, koniugat, izolowany kwas nukleinowy, wektor, komórka gospodarza i sposób wytwarzania przeciwciała
CA2387108A1 (en) 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
MXPA03004883A (es) 2000-12-01 2004-05-04 Battelle Memorial Institute Metodo para la estabilizacion de biomoleculas (por ejemplo, insulina) en formulaciones liquidas.
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
EP1507793A4 (en) 2001-10-17 2006-02-01 Human Genome Sciences Inc NEUTROKIN ALPHA AND NEUTROKIN ALPHA SPLICE VERSION
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
KR101033196B1 (ko) 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
PT1558648E (pt) 2002-10-17 2012-04-23 Genmab As Anticorpos monoclonais humanos contra cd20
AR042485A1 (es) 2002-12-16 2005-06-22 Genentech Inc Anticuerpo humanizado que se une al cd20 humano
KR101412271B1 (ko) 2003-05-09 2014-06-25 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006262603B2 (en) 2005-06-20 2011-01-06 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7390788B2 (en) * 2005-06-23 2008-06-24 Pert Candace B Peptide pharmaceutical compositions
CA2743725A1 (en) * 2006-06-23 2007-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) * 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008012062A1 (en) * 2006-07-24 2008-01-31 Polymun Scientific Immunbiologische Forschung Gmbh Antigenic proteoliposomes and method of manufacture
PL3586826T3 (pl) 2010-06-24 2021-10-25 F. Hoffmann-La Roche Ag Kompozycje i sposoby stabilizowania preparatów zawierających białka
JP5731726B1 (ja) 2014-06-26 2015-06-10 楽天株式会社 情報処理装置、情報処理方法及び情報処理プログラム

Also Published As

Publication number Publication date
JP2013533244A (ja) 2013-08-22
CA2802756C (en) 2021-05-04
CN103068367A (zh) 2013-04-24
CA3111727C (en) 2022-07-26
MX339666B (es) 2016-06-03
PL2585045T3 (pl) 2020-01-31
JP5894154B2 (ja) 2016-03-23
KR20180130590A (ko) 2018-12-07
HRP20191878T1 (hr) 2019-12-27
HRP20211056T1 (hr) 2021-10-01
BR112012033002B1 (pt) 2021-10-13
AU2011270828B2 (en) 2015-09-24
ES2751381T3 (es) 2020-03-31
US20130224213A1 (en) 2013-08-29
US10188735B2 (en) 2019-01-29
ES2880802T3 (es) 2021-11-25
EP4008313A1 (en) 2022-06-08
MY184736A (en) 2021-04-20
EP3586826A1 (en) 2020-01-01
KR102058307B1 (ko) 2019-12-20
NZ605147A (en) 2014-12-24
MX2012014862A (es) 2013-03-25
BR112012033002A2 (pt) 2016-12-20
KR101924653B1 (ko) 2018-12-03
WO2011163458A2 (en) 2011-12-29
ZA201209539B (en) 2015-03-25
MY161390A (en) 2017-04-14
EP3586826B1 (en) 2021-05-12
PL3586826T3 (pl) 2021-10-25
US11103584B2 (en) 2021-08-31
EP2585045B1 (en) 2019-08-21
EP2585045A2 (en) 2013-05-01
KR20130098283A (ko) 2013-09-04
IL254354B (en) 2021-05-31
IL254354A0 (en) 2017-11-30
AU2011270828A1 (en) 2013-01-17
SG186783A1 (en) 2013-02-28
CA2802756A1 (en) 2011-12-29
RU2013103025A (ru) 2014-07-27
AU2011270828A2 (en) 2013-02-07
SI2585045T1 (sl) 2019-11-29
IL223651A (en) 2017-09-28
WO2011163458A3 (en) 2012-06-07
US20190216929A1 (en) 2019-07-18
CA3111727A1 (en) 2011-12-29
US20160199494A1 (en) 2016-07-14
US9254321B2 (en) 2016-02-09
US11938189B2 (en) 2024-03-26
CN103068367B (zh) 2016-09-07
US20210353756A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
PL2550018T3 (pl) Kompozycje i sposoby użyteczne do stabilizowania preparatów zawierających białko
PL3586826T3 (pl) Kompozycje i sposoby stabilizowania preparatów zawierających białka
EP2446031A4 (en) ALKYLGLYCOSIDE STABILIZING COMPOSITIONS AND METHODS OF USE THEREOF
EP2585574A4 (en) AROMA COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
EP2646468A4 (en) ANTI-NGF COMPOSITIONS AND THEIR USE
IL221748B (en) Concentrated protein preparations and their uses
IL223153A0 (en) Compositions comprising acid and derivatives thereof and uses thereof
ZA201209259B (en) Uses and compositions
PH12013500698A1 (en) Hair-mending compositions and associated methods
SI2605757T1 (sl) Formulacije na osnovi nalbufina in njihove uporabe
GB201005625D0 (en) Immunogenic proteins and compositions
GB201103423D0 (en) Immunogenic proteins and compositions
EP2729164A4 (en) FORMULATIONS STABILIZING PROTEINS
GB201018650D0 (en) Methods and compositions
ZA201300194B (en) Formulations
GB201110193D0 (en) Formulations
GB201013513D0 (en) Formulations
ZA201300196B (en) Formulations
GB201009767D0 (en) Compositions and methods
GB201010083D0 (en) Compositions and methods
GB201018651D0 (en) Methods and compositions
GB201018647D0 (en) Formulations
GB201018649D0 (en) Formulations
GB201008470D0 (en) Formulations
GB201018648D0 (en) Formulations